Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended progression-free survival of people with an aggressive form of brain cancer. The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world’s largest maker of cancer drugs, said in a statement on Friday. “This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy,” Roche said.
